

**STATEMENT OF AUTHORITY
AND
CONFIDENTIALITY COMMITMENT FROM
THE PHARMACEUTICAL SAFETY BUREAU, MINISTRY OF HEALTH, LABOUR,
AND WELFARE AND THE PHARMACEUTICALS AND MEDICAL DEVICES
AGENCY OF JAPAN
NOT TO PUBLICLY DISCLOSE NON-PUBLIC INFORMATION SHARED
BY
THE UNITED STATES FOOD AND DRUG ADMINISTRATION**

The United States Food and Drug Administration (FDA) is authorized under 21 C.F.R. § 20.89¹ to disclose non-public information to The Pharmaceutical Safety Bureau (PSB), Ministry of Health, Labour, and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan regarding FDA-regulated drugs, including pre- and post-market activities, as appropriate, as part of cooperative law enforcement or cooperative regulatory activities. FDA is further authorized under section 708(c) of the Federal Food, Drug, and Cosmetic Act² to share with a foreign government, as it deems appropriate and under limited circumstances, certain types of trade secret information.

The Commissioner of Food and Drugs has certified PSB and PMDA as having the authority and demonstrated ability to protect trade secret information regarding trade from disclosure. FDA therefore may provide PSB and PMDA with certain types of trade secret information at FDA's discretion and upon request by PSB and PMDA, based on the following certifications.

PSB and PMDA understand that some of the information it receives from FDA may include non-public information exempt from public disclosure, such as commercially confidential information; trade secret information; personal privacy information; law enforcement information; designated national security information; or internal, pre-decisional information. PSB and PMDA understand that this non-public information is shared in confidence and that it is critical that PSB and PMDA maintain the confidentiality of exchanged non-public information. Public disclosure of exchanged non-public information by PSB and PMDA could seriously jeopardize any further scientific and regulatory interactions between PSB and PMDA and FDA. FDA will advise PSB and PMDA of the non-public status of the information at the time that the information is shared.

Therefore, PSB and PMDA certify that they:

1. have the authority to protect from public disclosure such non-public information provided to PSB and PMDA in confidence by FDA;
2. will not publicly disclose such FDA-provided non-public information without the written authorization of the owner of the information, the written authorization from the individual who is the subject of the personal privacy information, or a written statement from FDA providing that the information no longer has non-public status;

¹ United States Code of Federal Regulations, Title 21, section 20.89.

² United States Code, Title 21, section 379(c).

3. will protect trade secret information that FDA may provide from disclosure unless and until PSB and PMDA are in possession of a written permission for disclosure by the sponsor of the information provided by FDA, or alternatively of a declaration from the Commissioner of Food and Drugs of a public health emergency under section 319 of the Public Health Service Act that is relevant to the information;
4. with respect to trade secret information concerning the inspection of a drug facility, have the authority to otherwise obtain such information and will use such FDA-provided information only for civil, administrative regulatory purposes in the context of its mission;
5. will promptly inform FDA of any effort made by judicial or legislative mandate to obtain FDA-provided non-public information from PSB and PMDA. If such judicial or legislative mandate requires disclosure of FDA-provided non-public information, PSB and PMDA will take all appropriate legal measures in an effort to ensure that the information will be disclosed in a manner that protects the information from public disclosure;
6. will promptly inform FDA of any changes to Japan's laws, or to any relevant policies or procedures, that would affect PSB and PMDA's ability to honor the commitments in this document;
7. has established and will maintain compliance with standards consistent with current United States federal government National Institute of Standards and Technology (NIST) Risk Management and Cybersecurity Frameworks ³ and/or International Organization for Standardization and International Electrotechnical Commission (ISO/IEC) ⁴ Information Technology security guidelines and standards and National Center of Incident Readiness and Strategy for Cybersecurity (NISC)⁵ guidelines and standards that focus on protecting information systems and shared sensitive information;
8. will safeguard information systems that contain FDA-provided non-public information consistent with current NIST and/or ISO/IEC and NISC guidelines and standards to ensure confidentiality and integrity. Confidentiality means preventing unauthorized access to and disclosure of non-public information, and integrity means guarding against improper information modification or destruction. Integrity includes ensuring information non-repudiation and authenticity based on the security terms found in this Statement of Authority and Confidentiality Commitment, including means for protecting non-public information;
9. will destroy FDA-provided non-public information, whether in electronic form or hard copy form, once the information has been utilized and is no longer needed for official purposes;

³ The National Institute of Standards and Technology (NIST) Risk Management and Cybersecurity Frameworks provide a process that integrates security, privacy, and cyber supply chain risk management activities into the system development life cycle and provides guidance based on standards, guidelines, and practices for organizations to manage and reduce cybersecurity risk, respectively. These frameworks are primarily intended to manage and mitigate cybersecurity risk for critical infrastructure organizations based on standards, guidelines, and practices.

⁴ The International Organization for Standardization and International Electrotechnical Commission (ISO/IEC) is an international standard that assists organizations in managing the security of their information assets. It provides a management framework for implementing an information security management system to ensure the confidentiality of all corporate data. Foreign counterparts are strongly encouraged to meet the ISO 27001 standard requirements, or the most recent standard, and to be certified by an accredited certification body.

⁵ The National Center of Incident Readiness and Strategy for Cybersecurity (NISC) has a role as the secretariat of the Cyber Security Strategy Headquarters in Japan. NISC coordinates cybersecurity policy and set the common standards on information security measures of government entities to raise the level of information security for all governmental agencies and related agencies, as the baseline standard. Based on the standard, NISC oversees the status of implementation of it across agencies by audits.

10. will restrict access to FDA-provided non-public information to the employees, and officials of PSB and PMDA who require access to such non-public information to perform their official duties in line with authorized uses of the non-public information unless otherwise authorized in writing by FDA. PSB and PMDA will advise all such employees and officials of (1) the non-public nature of the information; and (2) the obligation to keep such information non-public; and

11. will, in the event of a suspected or confirmed incident or breach⁶, including a cybersecurity⁷ incident, or any other type of breach, whether it is intentional or inadvertent:

- (a) protect all FDA-provided non-public information, including any non-public information created, stored, or transmitted to avoid a secondary information incident;
- (b) report all suspected and confirmed incidents or breaches involving FDA-provided non-public information in any medium or form, including paper, oral, or electronic, to FDA as soon as possible and without unreasonable delay, no later than one (1) day of discovery or detection; and
- (c) provide to FDA impact and severity assessments of incidents or breaches, upon occurrence, including a description of the actions taken, including preventative security measures employed to address and remediate the incident.

This text is not intended to create rights and obligations under the domestic laws of either Japan or the United States or under international law.

Signed on behalf of PSB and PMDA:

-/s/-
MIYAMOTO Naoki
Director General of the Pharmaceutical
Safety Bureau, Ministry of Health, Labour
and Welfare

2-2 Kasumigaseki 1-chome, Chiyoda-ku,
Tokyo 100-8916, Japan

Date: ____ July 23, 2026 ____

-/s/-
Dr. FUJIWARA Yasuhiro
Chief Executive of the Pharmaceuticals and
Medical Devices Agency

Shin-Kasumigaseki Building,
3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo
100-0013, Japan

Date: ____ July 23, 2026 ____

⁶ An incident is defined as “an occurrence that (1) actually or imminently jeopardizes, without lawful authority, the confidentiality of information or an information system; or (2) constitutes a violation or imminent threat of violation of law, security policies, security procedures, or acceptable use policies.” Incidents can be events involving cybersecurity and privacy threats, such as viruses, malicious user activity, loss of confidentiality or integrity, unauthorized disclosure or destruction of information. For the purposes of this agreement, breach is defined as an actual compromise of security that results in the unauthorized disclosure of, loss, accidental or unlawful destruction, alteration, or access to protected data transmitted, stored, or otherwise processed. Breaches can be intentional or inadvertent.

⁷ Cybersecurity is the prevention of damage to, protection of, and restoration of computers, electronic communications systems, electronic communications services, wire communication, and electronic communication, including information contained therein, to ensure its availability, integrity, authentication, confidentiality, and nonrepudiation.